<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944225</url>
  </required_header>
  <id_info>
    <org_study_id>MN ORS</org_study_id>
    <nct_id>NCT04944225</nct_id>
  </id_info>
  <brief_title>Opiod Reduction Strategy South Western Ontario</brief_title>
  <official_title>Implementation of a Multi-faceted Opioid-Use Reduction Strategy for South Western Ontario: A Pragmatic Stepped-Wedge Cluster Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain is a major risk factor for chronic postoperative pain. Adequate perioperative pain&#xD;
      relief is an important metric for patient satisfaction and to achieve good recovery outcomes.&#xD;
      Opioids remain the primary systemic pharmacotherapy for intraoperative and postoperative&#xD;
      analgesia, particularly for moderate to severe pain. When used judiciously, opioids are&#xD;
      effective in reducing suffering and helping patients cope with postoperative pain. However,&#xD;
      there are challenges - a) side effects can result in harm, like respiratory depression; b)&#xD;
      over-reliance on opioids can increase drug dependency; c) over-prescription can encourage&#xD;
      addiction, overdose and death, leading to a human and financial burden from both, an&#xD;
      individual, and public health standpoint.1,2 Over-prescription of opioids for acute pain is&#xD;
      strongly linked to patient morbidity and mortality.3-9 For example, a new opioid prescription&#xD;
      raises the risk of lethal or non-lethal overdose, as well as the conversion from opioid-naive&#xD;
      to chronic user.10 Canadian Institute of Health Information (CIHI), and Public Health Agency&#xD;
      of Canada (PHAC) data emphasize the public health need to reduce reliance on opioids: &quot;From&#xD;
      January 2016 to June 2018, more than 9,000 Canadians died from apparent opioid related harms.&#xD;
      In 2017, an average of 17 Canadians were hospitalized for opioid poisonings each day - an&#xD;
      increase from 16 per day in 2016&quot;.11,12 Prescription opioid use appears to be an early driver&#xD;
      of the current crisis.13 Given the local and national severity of the opioid crisis, there is&#xD;
      need for a pragmatic, timely, and scalable intervention to reduce reliance on opioids as we&#xD;
      strive to improve healthcare for patients and alleviate the economic burden on the medical&#xD;
      system. Our proposal for a stepped-wedge randomized trial of a multi-faceted opioid-use&#xD;
      reduction strategy addresses key drivers of the opioid crisis and has the potential to reduce&#xD;
      patient exposure to opioids and, thereby, improve morbidity and mortality. Hospitals involved&#xD;
      in this study will all eventually participate in an opiod reduction strategy that will limit&#xD;
      the access and prescription of opiods to surgical patients and will incorporate various opiod&#xD;
      reductoin strategies at both a patient and hospital level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proposed Trial Design The proposed prospective randomized trial will employ a stepped-wedge&#xD;
      design, which is a variant of a cluster randomized trial. This is a pragmatic, two-armed,&#xD;
      parallel group registry based, cluster RCT. This SWAHN associated hospitals trial will be&#xD;
      embedded into routine care (new standard of care) with implementation of the intervention&#xD;
      delivered by perioperative personnel rather than research staff. Patient characteristics and&#xD;
      outcomes will be obtained from ICES administrative health care database. This pragmatic&#xD;
      design allows broad inclusion of the south west LHIN hospitals and a large representative&#xD;
      sample of perioperative patients that should yield highly generalizable findings. The&#xD;
      hospitals will be randomized (1:1) with concealed allocation methods and hospitals will be&#xD;
      notified of their group allocation by the study team 2 months before the intervention start&#xD;
      date.&#xD;
&#xD;
      Choice of study design In this trial, the unit of randomization is the cluster (i,e each of&#xD;
      the hospital) and the unit of analysis is the patient. We chose a cluster randomized design&#xD;
      to enhance intervention uptake and adherence (logistical convenience) and to minimize&#xD;
      cross-group contamination. Perioperative patients typically receive all their intervention at&#xD;
      the same centre, making this population suitable for cluster-level interventions. Delivery of&#xD;
      the opioid reduction strategy intervention in this cluster trial follows what occurs in&#xD;
      routine care, where the perioperative team in each hospital will be trained to follow the&#xD;
      same protocol or policy for patients under their care.&#xD;
&#xD;
      This will entail the roll out of the intervention in a randomized fashion and &quot;sequential&#xD;
      crossover of clusters from control to intervention until all clusters are exposed&quot;.14 This&#xD;
      type of trial is a pragmatic approach to investigate and implement a service delivery change,&#xD;
      given that the intervention will occur at the institutional level and individual patients&#xD;
      will not need to be randomized.14 This multi-centre, stepped-wedge cluster- RCT is designed&#xD;
      to evaluate the benefits of an opioid reduction strategy compared to standard practice as per&#xD;
      local hospital protocol, in patients undergoing elective surgical procedures, who are&#xD;
      prescribed opioids to control acute post- operative pain.15,16 In order to overcome data&#xD;
      collection challenges, we will collect the outcomes from all elective surgical patients (no&#xD;
      exclusions) from electronic databases ICES for the pre- and post-intervention. Following a&#xD;
      2-month baseline period in which all sites use their usual standard-of-care opioid&#xD;
      prescription, one of the randomly selected sites will begin implementing and following the&#xD;
      opioid reduction strategy; other sites will be randomly added to the intervention group every&#xD;
      two months until the strategy is in place at all the sites (total 12 months of data&#xD;
      collection; please see figure 1). One month before crossover to the phase of opioid reduction&#xD;
      strategy at each site, all anesthesia and research staff at the hospital site will be trained&#xD;
      by the study PI (Mahesh Nagappa) on the various intervention components, on implementing the&#xD;
      opioid reduction strategy, and on collection of data.&#xD;
&#xD;
      Study Setting Twelve hospitals within the Southwestern Ontario Academic Hospital Network&#xD;
      (SWAHN) will be invited to participate. London Health Sciences Centre and St. Joseph's&#xD;
      Healthcare London will be the lead sites. For this study, we have selected the perioperative&#xD;
      setting in which opioid analgesia prescribing is common during the hospital discharge.&#xD;
&#xD;
      Participants Recruited patients will be those receiving postoperative analgesia at&#xD;
      participating study sites after undergoing an elective surgical procedure. Given that the&#xD;
      intervention will be implemented on an institutional-wide level (e.g. via changing hospital&#xD;
      order sets and protocols), there will be no need to randomize individual patients. Since the&#xD;
      intervention is focused on opioid use post-discharge, intraoperative and post-operative pain&#xD;
      management will not be specified in the opioid reduction strategy. In-hospital pain&#xD;
      management will be at the discretion of the attending anesthesiologist, as described&#xD;
      elsewhere in the literature.&#xD;
&#xD;
      Planned trial interventions Control group: Pain management during the standard of care phase&#xD;
      In the standard of care phase, anesthetic and surgical care will be as per standard practice&#xD;
      (according to local hospital protocol) for both the control and the intervention group.&#xD;
      Generally, this means patients will be maintained on a more liberal opioid regime than in the&#xD;
      opioid reduction strategy phase and will receive opioid and other medications for the acute&#xD;
      postoperative pain. The choice of opioids will be at the discretion of the managing team.&#xD;
      There will be a minimum 2-month baseline period before entry of the first randomized cluster&#xD;
      to the intervention arm.&#xD;
&#xD;
      Intervention group: Pain management in the opioid reduction strategy phase The opioid&#xD;
      reduction strategy, including the tools and locally contextualized approach to&#xD;
      implementation, will be co-designed by a multi-disciplinary team of surgeons,&#xD;
      anesthesiologists, pharmacists, and researchers with expertise in knowledge translation,&#xD;
      together with patient representatives. To ensure indigenous perspectives are integrated, one&#xD;
      of the patient representatives will be from the local indigenous community.&#xD;
&#xD;
      The intervention will involve a multi-faceted 3 component (please see the supplementary file)&#xD;
      approach involving 1) opioid prescription caps (default maximum number of tablets for&#xD;
      discharge prescriptions, as defined by evidence-based guidelines, such as&#xD;
      https://michigan-open.org/prescribing-recommendations/ and&#xD;
      https://www.hqontario.ca/evidence-to-improve-care/quality-standards/view-all-quality-standard&#xD;
      s/opioid-prescribing-for-acute-pain, 2) patient education tools (e.g. What is a normal pain&#xD;
      trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia.&#xD;
      Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider&#xD;
      education tools (e.g. including procedure-specific evidence-based recommendations for&#xD;
      multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary&#xD;
      prescribing patterns; defining targeted reduction if baseline prescribing is at odds with&#xD;
      best evidence; review of best evidence about optimal analgesia perioperatively), and 4)&#xD;
      bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and&#xD;
      until end-of-study.&#xD;
&#xD;
      The strategy for implementing each of these components will be contextualized in&#xD;
      collaboration with the multidisciplinary team from each hospital prior to entry to the active&#xD;
      intervention phase, through meetings with the SWAHN Opioid Choosing Wisely Committee, and&#xD;
      with local meetings intensified during the first weeks of the active intervention.&#xD;
&#xD;
      Practical arrangements for allocating participants to trial groups Each hospital will be&#xD;
      randomly assigned to one of the crossover dates prior to the start of the study by a&#xD;
      statistician who is blinded to hospital identities, using a computer-generated list of random&#xD;
      numbers.&#xD;
&#xD;
      Proposed methods for protecting against sources of bias It is not possible to blind&#xD;
      clinicians or study staff to hospital allocation because the appropriate pain/opioid&#xD;
      management must be transparently applied upon entry to the intervention phase of the study,&#xD;
      and therefore the unit of randomization is at the hospital level. Outcome adjudicators will&#xD;
      be blinded and patients will remain blinded. We anticipate low risk of selection bias at the&#xD;
      patient level because all eligible patients will be enrolled in the study. From our previous&#xD;
      experience, we expect few (&lt;5%) participants to refuse consent to use their data.&#xD;
&#xD;
      Proposed duration of treatment period Clinicians will abide by the appropriate opioid&#xD;
      reduction strategy algorithms. The duration of the opioid reduction strategy phase will vary&#xD;
      at each hospital based on the randomization schedule, ranging from 4 to 12 months.&#xD;
&#xD;
      Proposed frequency and duration of follow up We will collect data on patients from PODs 1 (or&#xD;
      hospital discharge, whichever comes first), and POD 30 (or death, whichever comes first).&#xD;
&#xD;
      Sample size and power calculations As expected, we found that the sample size calculation is&#xD;
      very tricky for this prospective stepped wedge trial. We were originally aiming for sample&#xD;
      size calculations based on the Hussey &amp; Hughes approach, for analysis with fixed time effects&#xD;
      and random cluster effects. However, we settled on estimating the outcome based on the&#xD;
      available power, as the available sample size was very large (&gt;8,000 per month).17 We will&#xD;
      co-opt the ICES statistical team for the analysis, along with one of our local statistical&#xD;
      experts. This way we will navigate the layers of complexity to overcome our analysis plan.&#xD;
      The methods for adjusting for confounders has evolved significantly in recent years. If we&#xD;
      consider that there are multiple levels of potential confounders, uneven contamination over&#xD;
      time/cluster sizes, larger intracluster correlations, hospital level clustering, and&#xD;
      physician level clustering, then the large number of patients across 12 hospitals&#xD;
      (7000-8000/month), we will likely have greater than 90% power to detect a 25% reduction in&#xD;
      morphine equivalents, even with worst case scenario estimates for above mentioned clustering&#xD;
      and confounders. Using hospital statistics data, we estimate that &gt;8000 eligible patients&#xD;
      would be registered across 12 SWAHN hospitals over 4 weeks, with a 25% effect size in the&#xD;
      MME, and a between hospital coefficient of variation of 0.15. Assuming a constant case-load&#xD;
      during the pandemic, independent hospital effects and a 5% significance level, the trial&#xD;
      would have &gt;90% power to detect a 25% reduction in MME. If the assumption of independent&#xD;
      hospital effects was not met, and the 12 SWAHN hospital clusters functioned effectively as 12&#xD;
      large hospitals, power would be still &gt;80%.&#xD;
&#xD;
      Statistical Analysis Analyses will be carried out using intention-to-treat, based on the date&#xD;
      each hospital is assigned to cross over rather than the actual crossover date. With the&#xD;
      patient as the unit of analysis, we will determine the effect of the intervention on primary&#xD;
      and secondary outcomes. We will use generalized linear mixed models (GLMM) with logit link&#xD;
      for the binary outcome and random intercept to account for the clustering of patients within&#xD;
      hospitals. The model will adjust for patient characteristics (e.g., age, obesity, OSA etc)&#xD;
      and for time (secular trends). A time by treatment interaction will be tested. The effect of&#xD;
      the intervention will be estimated by odds ratios (OR) and 95% confidence intervals (CI) in&#xD;
      the final model. Secondary outcomes will be analyzed using GLMM for binary outcomes, linear&#xD;
      mixed model for continuous outcome (assuming normal distribution) and survival analysis for&#xD;
      length of hospital stay. Rate of missing data should be low (&lt;5%) as outcomes are routinely&#xD;
      collected to guide clinical care. Statistical significance will be defined as P&lt;0.05 or 95%&#xD;
      confidence intervals that exclude the null effect. All analyses will be conducted using the&#xD;
      intention-to-treat approach. We will analyze the primary outcome (and all other continuous&#xD;
      variables) using mixed-effects linear regression, with the intervention and time as fixed&#xD;
      effects in the model.&#xD;
&#xD;
      A random intercept and slope for time defined at the cluster level will account for&#xD;
      within-period and between-period intracluster correlations. Considering the relatively small&#xD;
      number of clusters, we will use the Kenward-Roger correction to avoid a potentially inflated&#xD;
      type I error rate. The binary secondary outcomes will be analyzed using a similar approach,&#xD;
      but with mixed-effects logistic regression models. Outcomes will also be stratified according&#xD;
      major types of surgery. Statistical analyses will be performed using SAS and R statistical&#xD;
      package.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Stepped-Wedge Cluster Randomized Trial. In this trial, the unit of randomization is the cluster (i,e each of the hospital) and the unit of analysis is the patient.This will entail the roll out of the intervention in a randomized fashion and &quot;sequential crossover of clusters from control to intervention until all clusters are exposed&quot;.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>It is not possible to blind clinicians or study staff to hospital allocation because the appropriate pain/opioid management must be transparently applied upon entry to the intervention phase of the study, and therefore the unit of randomization is at the hospital level. Outcome adjudicators will be blinded and patients will remain blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>total morphine milliequivalents (MME)</measure>
    <time_frame>Time of discharge up to 30 days postoperatively</time_frame>
    <description>The total morphone milliequivalents (MME) prescribed for each patient will be recorded by extracting this data from the ICES administrative healthcare database.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serious opioid-related events</measure>
    <time_frame>Time of discharge up to 30 days postoperatively</time_frame>
    <description>The aggregate of over-dose related death, cardiac arrest, respiratory depression, naloxone use, or opioid-related ED visit. Data will be extracted from the ICES administrative healthcare database.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission to hospital</measure>
    <time_frame>Time of discharge up to 90 days postoperatively</time_frame>
    <description>Instances patients may have been readmitted to hospital up to 90 days after discharge.Data will be extracted from the ICES administrative healthcare database.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of discharge</measure>
    <time_frame>Up to 90 days post operatively</time_frame>
    <description>The point post-operatively that the patient is discharged from hospital.Data will be extracted from the ICES administrative healthcare database.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion from opioid na√Øve to chronic user</measure>
    <time_frame>90 days post operatively</time_frame>
    <description>Measurement of how many patients are continuing to use opiods 90 post operatively.Data will be extracted from the ICES administrative healthcare database.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total opioid community exposure</measure>
    <time_frame>90 days post operatively</time_frame>
    <description>Morphine equivalents discharged to community via postoperative prescriptions.Data will be extracted from the ICES administrative healthcare database.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite outcome of &quot;days alive, out-of-hospital, and opioid-free at 90 days</measure>
    <time_frame>90 days post operatively</time_frame>
    <description>This is a composite outcome that simultaneously incorporates implications of death, readmissions, and opioid-use, and allows for comparison between intervention and control groups. Describes the numbers of patients who are alive, out of hospital and opiod free 90 days post operatively.Data will be extracted from the ICES administrative healthcare database.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Control group: Pain management during the standard of care phase</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the standard of care phase, anesthetic and surgical care will be as per standard practice (according to local hospital protocol) for both the control and the intervention group. Generally, this means patients will be maintained on a more liberal opioid regime than in the opioid reduction strategy phase and will receive opioid and other medications for the acute postoperative pain. The choice of opioids will be at the discretion of the managing team. There will be a minimum 2-month baseline period before entry of the first randomized cluster to the intervention arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group: Pain management in the opioid reduction strategy phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Opiod Reduction Strategy</intervention_name>
    <description>The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.</description>
    <arm_group_label>Intervention group: Pain management in the opioid reduction strategy phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 18 years of age&#xD;
&#xD;
          -  Undergoing elective surgery during the study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahesh Nagappa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahesh Nagappa, MD</last_name>
    <phone>5196588500</phone>
    <phone_ext>34436</phone_ext>
    <email>mahesh.nagappa@lhsc.on.ca</email>
  </overall_contact>
  <reference>
    <citation>Canadian Centre on Substance Abuse and Addiction. Canadian Drug Summary: Prescription Opioids. 2017.</citation>
  </reference>
  <reference>
    <citation>Canadian Institute for Health Information. Opioid-Related Harms in Canada, December 2018</citation>
  </reference>
  <reference>
    <citation>Ontario Agency for Health Protection and Promotion (Public Health Ontario); Office of the Chief Coroner; Ontario Forensic Pathology Service; Ontario Drug Policy Research Network. Opioid mortality surveillance report: Anal opioid-related deaths Ontario July 2017-June 2018 Toronto, Queen's Print Ontario 2019</citation>
  </reference>
  <reference>
    <citation>Nagappa M, Weingarten TN, Montandon G, Sprung J, Chung F. Opioids, respiratory depression, and sleep-disordered breathing. Best Pract Res Clin Anaesthesiol. 2017 Dec;31(4):469-485. doi: 10.1016/j.bpa.2017.05.004. Epub 2017 May 22. Review.</citation>
    <PMID>29739536</PMID>
  </reference>
  <reference>
    <citation>Cozowicz C, Chung F, Doufas AG, Nagappa M, Memtsoudis SG. Opioids for Acute Pain Management in Patients With Obstructive Sleep Apnea: A Systematic Review. Anesth Analg. 2018 Oct;127(4):988-1001. doi: 10.1213/ANE.0000000000003549.</citation>
    <PMID>29958218</PMID>
  </reference>
  <reference>
    <citation>Gupta K, Nagappa M, Prasad A, Abrahamyan L, Wong J, Weingarten TN, Chung F. Risk factors for opioid-induced respiratory depression in surgical patients: a systematic review and meta-analyses. BMJ Open. 2018 Dec 14;8(12):e024086. doi: 10.1136/bmjopen-2018-024086.</citation>
    <PMID>30552274</PMID>
  </reference>
  <reference>
    <citation>Subramani Y, Nagappa M, Wong J, Patra J, Chung F. Death or near-death in patients with obstructive sleep apnoea: a compendium of case reports of critical complications. Br J Anaesth. 2017 Nov 1;119(5):885-899. doi: 10.1093/bja/aex341. Review.</citation>
    <PMID>29077813</PMID>
  </reference>
  <reference>
    <citation>Gupta K, Prasad A, Nagappa M, Wong J, Abrahamyan L, Chung FF. Risk factors for opioid-induced respiratory depression and failure to rescue: a review. Curr Opin Anaesthesiol. 2018 Feb;31(1):110-119. doi: 10.1097/ACO.0000000000000541. Review.</citation>
    <PMID>29120929</PMID>
  </reference>
  <reference>
    <citation>Bohnert ASB, Ilgen MA. Understanding Links among Opioid Use, Overdose, and Suicide. N Engl J Med. 2019 Jan 3;380(1):71-79. doi: 10.1056/NEJMra1802148. Review.</citation>
    <PMID>30601750</PMID>
  </reference>
  <reference>
    <citation>Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017 Mar 17;66(10):265-269. doi: 10.15585/mmwr.mm6610a1.</citation>
    <PMID>28301454</PMID>
  </reference>
  <reference>
    <citation>Kharasch ED, Brunt LM. Perioperative Opioids and Public Health. Anesthesiology. 2016 Apr;124(4):960-5. doi: 10.1097/ALN.0000000000001012. Review.</citation>
    <PMID>26808634</PMID>
  </reference>
  <reference>
    <citation>CIHI Opioid Prescribing in Canada: How Are Practices Changing? (cihi.ca) Ottawa. 2019</citation>
  </reference>
  <reference>
    <citation>Opioids. Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: Apparent opioid-related deaths in Canada (January 2016 to March 2019). Web Based Report. Ottawa Public Heal Agency Canada; Sept 2019 https//health-infobase.canada.ca/datalab/national-surveillance-opioid-mortality.html</citation>
  </reference>
  <reference>
    <citation>Bachhuber MA, Nash D, Southern WN, Heo M, Berger M, Schepis M, Cunningham CO. Reducing the default dispense quantity for new opioid analgesic prescriptions: study protocol for a cluster randomised controlled trial. BMJ Open. 2018 Apr 20;8(4):e019559. doi: 10.1136/bmjopen-2017-019559.</citation>
    <PMID>29678969</PMID>
  </reference>
  <reference>
    <citation>Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ. 2015 Feb 6;350:h391. doi: 10.1136/bmj.h391. Review.</citation>
    <PMID>25662947</PMID>
  </reference>
  <reference>
    <citation>Rennert L, Heo M, Litwin AH, De Gruttola V. Accounting for external factors and early intervention adoption in the design and analysis of stepped-wedge designs: Application to a proposed study design to reduce opioid-related mortality. medRxiv. 2020 Jul 29. pii: 2020.07.26.20162297. doi: 10.1101/2020.07.26.20162297. Update in: BMC Med Res Methodol. 2021 Mar 16;21(1):53.</citation>
    <PMID>32766601</PMID>
  </reference>
  <reference>
    <citation>Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials. 2007 Feb;28(2):182-91. Epub 2006 Jul 7. Review.</citation>
    <PMID>16829207</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Mahesh Nagappa</investigator_full_name>
    <investigator_title>Assistant Professor, Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Opiod Use</keyword>
  <keyword>Opiod Reduction</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>None. IPD will not be collected or shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

